Immunophilin ligands in peripheral nerve regeneration

• Autorzy: Behram Kandemir Y. , Sarikcioglu L.
• Języki publikacji: EN

Abstrakty

EN

Immunophilins are a family of receptors for immunosuppressive drugs like cyclosporin A, FK506, rapamycin and their non-immunosuppressive analogues, which are collectively referred to as immunophilin ligands. The present study aimed to review neuroprotective and neuroregenerative actions of immunophilin ligands on peripheral nerve injuries. The special emphasis was given to well-known immunosuppressive drug FK506. Its historical background, administration routes, dosages, neuroregenerative, neuroprotective actions, therapeutic time window in administration, action mechanism and side effects of FK506 were reviewed. (Folia Morphol 2015; 74, 4: 407–413)

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2015
• Tom: 74
• Numer: 4
• Opis fizyczny: p.407-413,ref.

Twórcy

autor

Behram Kandemir Y.

• Department of Anatomy, Akdeniz University Faculty of Medicine, Antalya, Turkey

autor

Sarikcioglu L.

• Department of Anatomy, Akdeniz University Faculty of Medicine, Antalya, Turkey

Bibliografia

• 1. Arii T, Kamiya T, Arii K, Ueda M, Nito C, Katsura KI, Katayama Y (2001) Neuroprotective effect of immunosuppressant FK506 in transient focal ischemia in rat: therapeutic time window for FK506 in transient focal ischemia. Neurol Res, 23: 755–760.
• 2. Avramut M, Achim CL (2002) Immunophilins and their ligands: insights into survival and growth of human neurons. Physiol Behav, 77: 463–468.
• 3. Avramut M, Achim CL (2003) Immunophilins in nervous system degeneration and regeneration. Curr Top Med Chem, 3: 1376–1382.
• 4. Bavetta S, Hamlyn PJ, Burnstock G, Lieberman AR, Anderson PN (1999) The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: neuroprotection and local regeneration. Exp Neurol, 158: 382–393.
• 5. Borel JF, Feurer C, Gubler HU, Stahelin H (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions, 6: 468–475.
• 6. Brecht S, Waetzig V, Hidding U, Hanisch UK, Walther M, Herdegen T, Neiss WF (2009) FK506 protects against various immune responses and secondary degeneration following cerebral ischemia. Anat Rec (Hoboken), 292: 1993–2001.
• 7. Brenner MJ, Fox IK, Kawamura DH, Yu VM, Lowe JB, 3rd, Hunter DA, Mackinnon SE (2004) Delayed nerve repair is associated with diminished neuroenhancement by FK506. Laryngoscope, 114: 570–576.
• 8. Brillantes AB, Ondrias K, Scott A, Kobrinsky E, Ondriasova E, Moschella MC, Jayaraman T, Landers M, Ehrlich BE, Marks AR (1994) Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell, 77: 513–523.
• 9. Bruck W, Friede RL (1990) Anti-macrophage CR3 antibody blocks myelin phagocytosis by macrophages in vitro. Acta Neuropathol, 80: 415–418.
• 10. Cameron AM, Steiner JP, Roskams AJ, Ali SM, Ronnett GV, Snyder SH (1995) Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux. Cell, 83: 463–472.
• 11. Chen S, Bisby MA (1993) Impaired motor axon regeneration in the C57BL/Ola mouse. J Comp Neurol, 333: 449–454.
• 12. Choi J, Chen J, Schreiber SL, Clardy J (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science, 273: 239–242.
• 13. Chunasuwankul R, Ayrout C, Dereli Z, Gal A, Lanzetta M, Owen E (2002) Low dose discontinued FK506 treatment enhances peripheral nerve regeneration. Int Surg, 87: 274–278.
• 14. Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH (1993) Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci USA, 90: 9808–9812.
• 15. De Koning P, Gispen WH (1987) Org.2766 improves functional and electrophysiological aspects of regenerating sciatic nerve in the rat. Peptides, 8: 415–422.
• 16. Diaz LM, Steele MH, Guerra AB, Aubert FE, Sloop GD, Diaz HA, Metzinger RC, Blake DB, Delaune CL, Metzinger SE (2004) The role of topically administered FK506 (tacrolimus) at the time of facial nerve repair using entubulation neurorrhaphy in a rabbit model. Ann Plast Surg, 52: 407–413.
• 17. Drake M, Friberg H, Boris-Moller F, Sakata K, Wieloch T (1996) The immunosuppressant FK506 ameliorates ischaemic damage in the rat brain. Acta Physiol Scand, 158: 155–159.
• 18. Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fischer PA, Sigal NH (1990) The immunosuppressive macrolides FK506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol, 144: 1418–1424.
• 19. Ekstrom AR, Kanje M, Skottner A (1989) Nerve regeneration and serum levels of insulin-like growth factor-I in rats with streptozotocin-induced insulin deficiency. Brain Res, 496: 141–147.
• 20. Fansa H, Keilhoff G, Altmann S, Plogmeier K, Wolf G, Schneider W (1999) The effect of the immunosuppressant FK 506 on peripheral nerve regeneration following nerve grafting. J Hand Surg Br, 24: 38–42.
• 21. Fansa H, Keilhoff G, Horn T, Altmann S, Wolf G, Schneider W (1999) Stimulation des Wachstums Schwannscher Zellen und der axonalen Regeneration peripherer Nerven durch das Immunsuppressivum FK 506. Handchir Mikrochir Plast Chir, 31: 323–329; discussion 330–322.
• 22. Feng FY, Ogden MA, Myckatyn TM, Grand AG, Jensen JN, Hunter DA, Mackinnon SE (2001) FK506 rescues peripheral nerve allografts in acute rejection. J Neurotrauma, 18: 217–229.
• 23. Fischer DW, Beggs JL, Kenshalo DL, Jr., Shetter AG (1985) Comparative study of microepineurial anastomoses with the use of CO2 laser and suture techniques in rat sciatic nerves: Part 1. Surgical technique, nerve action potentials, and morphological studies. Neurosurgery, 17: 300–308.
• 24. Furuichi Y, Katsuta K, Maeda M, Ueyama N, Moriguchi A, Matsuoka N, Goto T, Yanagihara T (2003) Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res, 965: 137–145.
• 25. Gillon RS, Cui Q, Dunlop SA, Harvey AR (2003) Effects of immunosuppression on regrowth of adult rat retinal ganglion cell axons into peripheral nerve allografts. J Neurosci Res, 74: 524–532.
• 26. Glazner GW, Lupien S, Miller JA, Ishii DN (1993) Insulin-like growth factor II increases the rate of sciatic nerve regeneration in rats. Neuroscience, 54: 791–797.
• 27. Gold BG (2000) Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Expert Opin Investig Drugs, 9: 2331–2342.
• 28. Gold BG, Armistead DM, Wang MS (2005) Non-FK506-binding protein-12 neuroimmunophilin ligands increase neurite elongation and accelerate nerve regeneration. J Neurosci Res, 80: 56–65.
• 29. Gold BG, Gordon HS, Wang MS (1999) Efficacy of delayed or discontinuous FK506 administrations on nerve regeneration in the rat sciatic nerve crush model: lack of evidence for a conditioning lesion-like effect. Neurosci Lett, 267: 33–36.
• 30. Gold BG, Katoh K, Storm-Dickerson T (1995) The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J Neurosci, 15: 7509–7516.
• 31. Gold BG, Yew JY, Zeleny-Pooley M (1998) The immunosuppressant FK506 increases GAP-43 mRNA levels in axotomized sensory neurons. Neurosci Lett, 241: 25–28.
• 32. Gold BG, Zeleny-Pooley M, Chaturvedi P, Wang MS (1998) Oral administration of a nonimmunosuppressant FKBP-12 ligand speeds nerve regeneration. Neuroreport, 9: 553–558.
• 33. Gorphe P, Guerout N, Birchall M, Terenghi G, Marie JP (2012) Tacrolimus enhances the recovery of normal laryngeal muscle fibre distribution after reinnervation. J Laryngol Otol, 126: 1155–1158.
• 34. Heitman J, Koller A, Kunz J, Henriquez R, Schmidt A, Movva NR, Hall MN (1993) The immunosuppressant FK506 inhibits amino acid import in Saccharomyces cerevisiae. Mol Cell Biol, 13: 5010–5019.
• 35. Hizay A, Demirel BM, Gokhan G, Sarikcioglu L, Demir N (2011) Does FK506 reduce the size of the watershed area after vascular injury of the sciatic nerve? Rom J Morphol Embryol, 52: 1077–1080.
• 36. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, Nourse J, Crabtree GR (1996) The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol, 80: S40–45.
• 37. Holmes W, Young JZ (1942) Nerve regeneration after immediate and delayed suture. J Anat, 77: 63–96.
• 38. Jin KB, Hwang EA, Han SY, Park SB, Kim HC, Ha EY, Suh SI, Mun KC (2008) Effects of tacrolimus on antioxidant status and oxidative stress in glioma cells. Transplant Proc, 40: 2740–2741.
• 39. Jost SC, Doolabh VB, Mackinnon SE, Lee M, Hunter D (2000) Acceleration of peripheral nerve regeneration following FK506 administration. Restor Neurol Neurosci, 17: 39–44.
• 40. Kanje M, Skottner A, Sjoberg J, Lundborg G (1989) Insulin-like growth factor I (IGF-I) stimulates regeneration of the rat sciatic nerve. Brain Res, 486: 396–398.
• 41. Kaplan S, Piskin A, Ayyildiz M, Aktas A, Koksal B, Ulkay MB, Turkmen AP, Bakan F, Geuna S (2011) The effect of melatonin and platelet gel on sciatic nerve repair: an electrophysiological and stereological study. Microsurgery, 31: 306–313.
• 42. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo), 40: 1249–1255.
• 43. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo), 40: 1256–1265.
• 44. Lane JM, Bora FW, Jr., Pleasure D (1978) Neuroma scar formation in rats following peripheral nerve transection. J Bone Joint Surg Am, 60: 197–203.
• 45. Laupacis A, Keown PA, Ulan RA, McKenzie N, Stiller CR (1982) Cyclosporin A: a powerful immunosuppressant. Can Med Assoc J, 126: 1041–1046.
• 46. Lee M, Doolabh VB, Mackinnon SE, Jost S (2000) FK506 promotes functional recovery in crushed rat sciatic nerve. Muscle Nerve, 23: 633–640.
• 47. Li X, Wang W, Wei G, Wang G, Zhang W, Ma X (2010) Immunophilin FK506 loaded in chitosan guide promotes peripheral nerve regeneration. Biotechnol Lett, 32: 1333–1337.
• 48. Liu J, Farmer JD, Jr., Lane WS, Friedman J, Weissman I, Schreiber SL (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell, 66: 807–815.
• 49. Ludwin SK, Bisby MA (1992) Delayed wallerian degeneration in the central nervous system of Ola mice: an ultrastructural study. J Neurol Sci, 109: 140–147.
• 50. Lyons WE, George EB, Dawson TM, Steiner JP, Snyder SH (1994) Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci USA, 91: 3191–3195.
• 51. Lyons WE, Steiner JP, Snyder SH, Dawson TM (1995) Neuronal regeneration enhances the expression of the immunophilin FKBP- 12. J Neurosci, 15: 2985–2994.
• 52. Madsen JR, MacDonald P, Irwin N, Goldberg DE, Yao GL, Meiri KF, Rimm IJ, Stieg PE, Benowitz LI (1998) Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after spinal cord injury in rats. Exp Neurol, 154: 673–683.
• 53. Menovsky T, Beek JF (2001) Laser, fibrin glue, or suture repair of peripheral nerves: a comparative functional, histological, and morphometric study in the rat sciatic nerve. J Neurosurg, 95: 694–699.
• 54. Morioka M, Hamada J, Ushio Y, Miyamoto E (1999) Potential role of calcineurin for brain ischemia and traumatic injury. Prog Neurobiol, 58: 1–30.
• 55. Mukai H, Kuno T, Chang CD, Lane B, Luly JR, Tanaka C (1993) FKBP12-FK506 complex inhibits phosphatase activity of two mammalian isoforms of calcineurin irrespective of their substrates or activation mechanisms. J Biochem (Tokyo), 113: 292–298.
• 56. Myckatyn TM, Ellis RA, Grand AG, Sen SK, Lowe JB, 3rd, Hunter DA, Mackinnon SE (2002) The effects of rapamycin in murine peripheral nerve isografts and allografts. Plast Reconstr Surg, 109: 2405–2417.
• 57. Nghiem P, Pearson G, Langley RG (2002) Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol, 46: 228–241.
• 58. Noto T, Ishiye M, Furuich Y, Keida Y, Katsuta K, Moriguchi A, Matsuoka N, Aramori I, Goto T, Yanagihara T (2004) Neuroprotective effect of tacrolimus (FK506) on ischemic brain damage following permanent focal cerebral ischemia in the rat. Brain Res Mol Brain Res, 128: 30–38.
• 59. Ohnishi H, Muto Y, Maeda T, Hayashi T, Nagaki M, Yamada T, Shimazaki M, Yamada Y, Sugihara J, Moriwaki H (1993) Natural killer cell may impair liver regeneration in fulminant hepatic failure. Gastroenterol Jpn, 28: 40–44.
• 60. Okajima S, Hojo T, Tamai K, Takai S, Hirasawa Y (2002) Histological and electrophysiological analysis of the peripheral nerve allografts using an immunosuppressive agent. Microsc Res Tech, 58: 52–58.
• 61. Park HJ, Rosado JA, Redondo PC, Cho YS (2011) Immunophilin dysfunction and neuropathology. Curr Med Chem, 18: 5398–5407.
• 62. Que J, Cao Q, Sui T, Du S, Kong D, Cao X (2013) Effect of FK506 in reducing scar formation by inducing fibroblast apoptosis after sciatic nerve injury in rats. Cell Death Dis, 4: e526.
• 63. Sabatini DM, Lai MM, Snyder SH (1997) Neural roles of immunophilins and their ligands. Mol Neurobiol, 15: 223–239.
• 64. Sarikcioglu L, Duygulu E, Aydin H, Gurer EI, Ozkan O, Tuzuner S (2006) Effects of intrathecal administration of FK506 after sciatic nerve crush injury. J Reconstr Microsurg, 22: 649–654.
• 65. Schmidt A, Hall MN, Koller A (1994) Two FK506 resistance-conferring genes in Saccharomyces cerevisiae, TAT1 and TAT2, encode amino acid permeases mediating tyrosine and tryptophan uptake. Mol Cell Biol, 14: 6597–6606.
• 66. Sharkey J, Butcher SP (1994) Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature, 371: 336–339.
• 67. Snyder SH, Sabatini DM (1995) Immunophilins and the nervous system. Nat Med, 1: 32–37.
• 68. Sporel-Ozakat RE, Edwards PM, Van der Hoop RG, Gispen WH (1990) An ACTH-(4-9) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats. Eur J Pharmacol, 186: 181–187.
• 69. Srinivas TR, Meier-Kriesche HU (2008) Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol, 3 (suppl. 2): S101–S116.
• 70. Sulaiman OA, Voda J, Gold BG, Gordon T (2002) FK506 increases peripheral nerve regeneration after chronic axotomy but not after chronic schwann cell denervation. Exp Neurol, 175: 127–137.
• 71. Sun L, Youn HD, Loh C, Stolow M, He W, Liu JO (1998) Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. Immunity, 8: 703–711.
• 72. Toll EC, Seifalian AM, Birchall MA (2011) The role of immunophilin ligands in nerve regeneration. Regen Med, 6: 635–652.
• 73. Udina E, Ceballos D, Gold BG, Navarro X (2003) FK506 enhances reinnervation by regeneration and by collateral sprouting of peripheral nerve fibers. Exp Neurol, 183: 220–231.
• 74. Ueki M, Yasunami Y, Ina K, Ryu S, Funakoshi A, Kamei T, Ikeda S (1993) Diabetogenic effects of FK506 on renal subcapsular islet isografts in rat. Diabetes Res Clin Pract, 20: 11–19.
• 75. Utuk A, Sarikcioglu L, Demirel BM, Demir N (2009) The immunosuppressive agent FK506 prevents subperineurial degeneration and demyelination on ultrastructural and functional analysis. Curr Neurovasc Res, 6: 252–258.
• 76. Wang MS, Gold BG (1999) FK506 increases the regeneration of spinal cord axons in a predegenerated peripheral nerve autograft. J Spinal Cord Med, 22: 287–296.
• 77. Wang MS, Zeleny-Pooley M, Gold BG (1997) Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve. J Pharmacol Exp Ther, 282: 1084–1093.
• 78. Yamamoto S, Kato R (1994) Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants. J Dermatol Sci, 7 (suppl.): S47–S54.
• 79. Yildirim FB, Sarikcioglu L, Ozsoy U, Demir N, Demirtop A, Ucar Y (2008) Effect of FK506 administration after obturator nerve injury: a functional and ultrastructural study. Acta Neurobiol Exp, 68: 477–483.
• 80. Zawadzka M, Kaminska B (2005) A novel mechanism of FK506-mediated neuroprotection: downregulation of cytokine expression in glial cells. Glia, 49: 36–51.

Identyfikatory

DOI

10.5603/FM.2015.0100